🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› China
Clinical trial register · China

Studies with a Chinese investigative site

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the register
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University490 Fudan University472 Second Affiliated Hospital, Zhejiang University, School of Medicine404 Peking Union Medical College Hospital282 Ruijin Hospital281
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to
19052 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
FOLFOX-HAIC as Conversion Treatment for Initially Unresectable Colorectal Liver Metastasis
NCT06988852Colorectal Liver Metastasis (CRLM)
Tongji Hospital
Phase 2
300
Wuhan
2023-05-01
Recruiting
Postoperative Radiotherapy in Thoracic Esophageal Squamous Cell Carcinoma With Neoadjuvant Chemoradiotherapy
NCT03734952Radiation Oncology
Fujian Medical University Union Hospital
Not applicable
537
Fuzhou
2023-05-01
Recruiting
Early PP Monitored by EIT in Patients With ARDS
NCT05822869Acute Respiratory Distress Syndrome
Beijing Chao Yang Hospital
Not applicable
60
Beijing
2023-05-01
Not yet open
Elemene Plus Stupp Protocol Versus Stupp Protocol Alone for Newly-diagnosed Glioblastoma
NCT05842746Glioblastoma, IDH-wildtype
Peking Union Medical College Hospital
Phase 2
74
Beijing
2023-05
Recruiting
Two Cycles VS Three Cycles Induction Chemotherapy in T1-4N2-3 Locally Advanced Nasopharyngeal Carcinoma
NCT05860868Locally Advanced Nasopharyngeal Carcinoma
First Affiliated Hospital, Sun Yat-Sen University
Phase 3
474
Guangzhou
2023-05
Not yet open
Clinical Outcomes of CT-FFR Versus QFR-guided Strategy for Decision-Making in Patients With Stable Chest Pain
NCT05857904Angina, Stable, Coronary Artery Disease
Shanghai Zhongshan Hospital
Not applicable
4,648
Shanghai
2023-05
Not yet open
Real World Study of Linperlisib for Lymphoma Treatment
NCT05863871Focus on the Lymphoma Including B/T-cell Lymphoma
Ruijin Hospital
Observational
1,000
Shanghai, Tianjin
2023-05
Recruiting
CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic Diseases
NCT05827835Hematologic Diseases, Neoplasms
Zhejiang University
Phase 1/2
30
Hangzhou
2023-04-30
Recruiting
Lenvatinib for Advanced Bone and Soft Tissue Sarcoma
NCT05617859Effectiveness, Sexuality
Henan Cancer Hospital
Phase 2
60
Zhengzhou
2023-04-30
Recruiting
Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
NCT05918094Gastric Cancer
Sun Yat-sen University
Phase 3
540
Guangzhou, Guiyang, Harbin, Zhengzhou, Wuhan, Nanchang, Dalian, Shanghai
2023-04-30
Recruiting
CDK4/6 Inhibitors in Patients With Hormone Receptor-positive Advanced Breast Cancer
NCT05795335Breast Cancer
RenJi Hospital
Observational
172
Shanghai
2023-04-30
Active, closed
Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma
NCT05869227Nasopharyngeal Carcinoma, Maintenance Therapy
XIANG YANQUN
Phase 3
166
Guangzhou
2023-04-28
Active, closed
Study of CT071 Injection in RRMM or PPCL
NCT05838131Multiple Myeloma, Primary Plasma Cell Leukemia
Shanghai Changzheng Hospital
Phase EARLY_PHASE1
20
Shanghai
2023-04-28
Active, closed
A Study of Telitacicept for IgA Nephropathy (TELIGAN)
NCT05799287Primary IgA Nephropathy
RemeGen Co., Ltd.
Phase 3
318
Bengbu, Hefei, Wuhu, Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou
2023-04-28
Recruiting
A Study of CM310 in Subjects With Moderate to Severe Asthma
NCT05761028Moderate to Severe Asthma
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2/3
600
Beijing
2023-04-28
Recruiting
Efficacy and Safety of Head Acupuncture After Mechanical Thrombectomy for Acute Ischemic Stroke
NCT05561088Acupuncture, Acute Ischemic Stroke, Mechanical Thrombectomy
Xi'an No.3 Hospital
Not applicable
272
Xi'an
2023-04-27
Active, closed
Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)
NCT05804045Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath
Abbisko Therapeutics Co, Ltd
Phase 3
94
Bengbu, Beijing, Fuzhou, Guangzhou, Guiyang, Zhengzhou, Enshi, Wuhan
2023-04-27
Recruiting
Stepwise Strategy for Treatment of Atrialfibrillation Substrate Study
NCT07129564Atrial Fibrillation
Yuehui Yin
Observational
480
Chongqing
2023-04-27
Recruiting
Personalized Tumor Vaccines and Pabolizumab in Patients With Advanced Pancreatic Cancer
NCT05916261Advanced Pancreatic Cancer
Ruijin Hospital
Phase EARLY_PHASE1
54
Qionghai
2023-04-26
Recruiting
A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
NCT06508307Sarcoma, Cervical Cancer, Colon Cancer, Lung Cancer
GONGCHU Biotechnology Co., Ltd
Phase 1
21
Zhengzhou
2023-04-26
Recruiting
Development and Validation of Microbiota and Metabolite-based Prediction Model for Recurrence of High-risk Colorectal Polyps After Polypectomy
NCT06957626Colorectal Polyp, Colorectal Cancer Recurrent, Colorectal Adenoma
Peking Union Medical College Hospital
Observational
150
Beijing
2023-04-25
Active, closed
Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors.
NCT05864014Chemotherapy-Induced Thrombocytopenia
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
213
Haerbin
2023-04-25
Recruiting
Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer
NCT05806060Triple-Negative Breast Cancer
Fudan University
Phase 3
134
Shanghai
2023-04-25
Recruiting
Registry of Acute Ischemic Stroke With Large- or Medium-vessel Occlusion
NCT05779215Acute Ischemic Stroke
Xuanwu Hospital, Beijing
Observational
50,000
Beijing
2023-04-25
Recruiting
The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma
NCT05741359Non-hodgkin Lymphoma,B Cell
Bioray Laboratories
Phase 1
18
Wuhan, Tianjin, Hangzhou
2023-04-25
Recruiting
Regorafenib Alone or in Combination With Hypofractionated/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer
NCT05963490Microsatellite Stable Metastatic Colorectal Cancer
Fudan University
Phase 2
108
Shanghai
2023-04-25
Recruiting
Effect of Gut Microbiome Intervention on Aging Via Oral FMT
NCT05598112Aging, Frailty
Chinese Academy of Medical Sciences, Fuwai Hospital
Phase EARLY_PHASE1
210
Beijing, Shanghai, Hangzhou
2023-04-24
Recruiting
Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer
NCT05744687Locally Advanced or Metastatic Breast Cancer
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 2/3
374
Fuzhou, Guangzhou, Guiyang, Anyang, Luoyang, Pingxiang, Changchun, Yinchuan
2023-04-24
Active, closed
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
NCT05775159Hepatocellular Carcinoma, Biliary Tract Cancer
AstraZeneca
Phase 2
294
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Harbin, Nanning, Shanghai
2023-04-24
Recruiting
A Study of BPI-460372 in Advanced Solid Tumor Patients
NCT05789602Advanced Solid Tumor
Betta Pharmaceuticals Co., Ltd.
Phase 1
82
Beijing, Baoding, Harbin, Wuhan, Changsha, Changchun, Jinan, Taizhou
2023-04-24
Active, closed
Long COVID and Its Associations With Health Outcomes in Older Adults
NCT05825651Long COVID, COVID-19 Pandemic, Elderly Infection, Vaccine Reaction
Peking University
Observational
11,527
Kunming
2023-04-24
Recruiting
Prognosis of Heart Transplanted Patients With Heart Failure
NCT05775432Heart Failure
First Affiliated Hospital Xi'an Jiaotong University
Observational
1,000
Xi'an
2023-04-23
Recruiting
Second-line Treatment of Metastatic Colorectal Cancer
NCT06242067Metastatic Colorectal Cancer
Qilu Hospital of Shandong University
Phase 2
50
Jinan
2023-04-23
Active, closed
Neoadjuvant Chemotherapy Plus Toripalimab in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
NCT05813626Nasopharyngeal Carcinoma
Zhejiang Cancer Hospital
Phase 2
89
Hangzhou
2023-04-21
Active, closed
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
NCT05805501Renal Cell Carcinoma
Hoffmann-La Roche
Phase 2
199
Beijing, Nanjing, Tianjin
2023-04-21
Active, closed
A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities
NCT05850286Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2023-04-21
Recruiting
PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer
NCT06792162Gastric Cancer
Peking University Third Hospital
Phase 2
20
Beijing
2023-04-20
Recruiting
A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors
NCT05785039Urinary System Tumor, Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
76
Shanghai
2023-04-20
Recruiting
A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
NCT05798819Persistent, Recurrent, or Metastatic Cervical Cancer
Guangzhou Gloria Biosciences Co., Ltd.
Phase 3
424
Shanghai
2023-04-20
Recruiting
A Randomized Controlled Study of High-dose Cyclophosphamide Induction Therapy in Adult Patients With HLH
NCT05936086Hemophagocytic Syndrome
shifeng Lou
Not applicable
160
Chongqing
2023-04-20
Recruiting
Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor
NCT05103345Advanced Solid Tumor
Guangzhou Sinogen Pharmaceutical Co., Ltd
Phase 1/2
70
Guangzhou, Chengdu
2023-04-19
Recruiting
Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma
NCT05738694Renal Cell Carcinoma, Neoadjuvant
ZHOU FANGJIAN
Phase 3
298
Beijing, Guangzhou, Hefei, Shanghai, Sichuan, Tianjin, Zhengzhou
2023-04-19
Recruiting
Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer
NCT06702995Metastatic Castrate-Resistant Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer)
Evopoint Biosciences Inc.
Phase 1/2
307
Jinan, Shanghai
2023-04-19
Recruiting
The Efficacy and Safety of ZS801 in Chinese Hemophilia B Patients.
NCT05630651Hemophilia B
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
6
Tianjin
2023-04-19
Recruiting
Effect of Music Therapy in Mental Subhealth (EMTMS)
NCT05648539Depression, Anxiety
Jiangsu Province Nanjing Brain Hospital
Not applicable
150
Nanjing
2023-04-19
Active, closed
Clinical Trial of Mica
NCT05680415Latent Tuberculosis Infection
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Phase 4
6,800
Liuzhou
2023-04-19
Active, closed
A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)
NCT05816252Non-small Cell Lung Cancer
Klus Pharma Inc.
Phase 2
356
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2023-04-19
Recruiting
Risk Factors for Stroke or Systemic Embolism in Chinese Patients with Non-Valvular Atrial Fibrillation Registry
NCT05598632Atrial Fibrillation, Stroke
China National Center for Cardiovascular Diseases
Observational
22,000
Beijing
2023-04-18
Recruiting
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
NCT05786924Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation
Institut de Recherches Internationales Servier
Phase 1/2
554
Beijing, Jinan, Shanghai, Suzhou
2023-04-18
Recruiting
Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections
NCT05639647Gram-negative Bacterial Infections
Pfizer
Phase 2
48
Beijing, Guangzhou, Shanghai
2023-04-18
Active, closed
A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy
NCT05707377Primary Membranous Nephropathy
BeOne Medicines
Phase 2/3
178
Beijing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Nanning, Guiyang, Shijiazhuang
2023-04-17
Recruiting
Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women
NCT04124120Heart Diseases, Coronary Artery Disease, Coronary Artery Bypass Grafting
Weill Medical College of Cornell University
Not applicable
2,300
Beijing, Changchun, Shanghai, Tianjin
2023-04-17
Recruiting
A Study of Telitacicept in Lupus Nephritis
NCT05680480Lupus Nephritis
RemeGen Co., Ltd.
Phase 2
120
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Liuzhou, Guiyang, Baoding
2023-04-17
Recruiting
Clinical Trial of Shugan Jieyu Capsule in Generalized Anxiety Disorder
NCT05772104Generalized Anxiety Disorder
Sichuan Jishengtang Pharmaceutical Co., Ltd.
Phase 3
495
Beijing
2023-04-17
Active, closed
A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors
NCT06299124Breast Cancer, Advanced Solid Tumor
Regor Pharmaceuticals Inc.
Phase 1
40
Shanghai
2023-04-17
By invitation
Effect of MRA on Cardiovascular Disease in Patients With Hypertension and Hyperaldosteronemia
NCT05688579Hypertension, Hyperaldosteronaemia
Nanfang Li
Phase 4
8,000
Ürümqi
2023-04-16
Active, closed
Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders
NCT05792462NMO Spectrum Disorder
Tianjin Medical University General Hospital
Phase 1
11
Tianjin
2023-04-15
Recruiting
A Real-world Study of 650nm Low-intensity Single-wavelength Red Light for Children and Adolescents
NCT05832723Myopia
Beijing Tongren Hospital
Observational
2,000
Beijing
2023-04-15
Recruiting
Comparison of the Therapeutic Effects of VR and VR + Metformin in the Treatment of Cesarean Section Scar Defect
NCT05205317Defect
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Not applicable
100
Shanghai
2023-04-15
Recruiting
Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors
NCT05689853Solid Tumor, Adult
Akeso
Phase 1/2
87
Beijing
2023-04-14
Recruiting
Drug Exposure and Minimum Inhibitory Concentration in the Treatment of MAC Lung Disease
NCT05824988Mycobacterium Avium Complex, Mycobacterium Avium-Intracellulare Infection, Gram-Positive Bacterial Infections, Mycobacterium Infections
Shanghai Pulmonary Hospital, Shanghai, China
Observational
100
Shanghai
2023-04-14
Recruiting
The Collagen Factors of Rapid Progression of Keratoconus in Children.
NCT06722937Keratoconus
Zhongshan Ophthalmic Center, Sun Yat-sen University
Observational
160
Guangzhou
2023-04-14
Active, closed
A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer
NCT05645692Urothelial Cancer
Hoffmann-La Roche
Phase 2
204
Beijing, Chengdu, Guangzhou, Shanghai
2023-04-13
Recruiting
A Randomized Controlled Study Evaluating Modified Cup Anteversion Placement in Prevention of Postoperative Dislocation in Patients Undergoing Acetabular Tumor Resection and Reconstruction
NCT05593146Periacetabular Tumor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
118
Ningbo
2023-04-13
Recruiting
A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer
NCT06202261Metastatic Breast Cancer, Recurrent Breast Cancer, Advanced Malignancies
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
154
Chongqing, Harbin
2023-04-13
Recruiting
The Effect of Dual Eradication Therapy vs PPI on Gastrointestinal Bleeding in ACS Patients
NCT04728516Acute Coronary Syndrome, Helicobacter Pylori Infection
Qilu Hospital of Shandong University
Phase 4
2,600
Bozhou, Chuzhou, Hefei, Beijing, Zunyi, Zhengzhou, Dalian, Xining
2023-04-12
Recruiting
Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer
NCT06141226Non-small-cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
148
Huizhou, Nanyang, Lianyungang, Weihai, Tianjin
2023-04-12
Recruiting
SY001 Targets Mesothelin in a Single-arm, Dose-increasing Setting in Subjects With Advanced Solid Tumors
NCT06562647Treatment Related Cancer, Ovarian Cancer
Cell Origin Biotech (Hangzhou) Co., Ltd.
Not applicable
2
Hangzhou, Linyi
2023-04-12
Recruiting
Immunotherapy with Autologous Tregs in T1DM
NCT06708780Type 1 Diabetes Mellitus
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 1
20
Nanjing
2023-04-12
Active, closed
TrEatment Approach in the Multimodal Era Registry
NCT05629052Chronic Thromboembolic Pulmonary Hypertension, CTEPH
International CTEPH Association
Observational
1,000
Beijing
2023-04-12
Recruiting
Clinical Study Protocol of Maintenance Therapy With Venetoclax in Elderly Patients With AML in First Complete Remission
NCT05909293Acute Myeloid Leukemia
The First Affiliated Hospital with Nanjing Medical University
Not applicable
100
Nanjing
2023-04-12
Active, closed
Safety and Efficacy Analysis of Oral Etoposide Combined With Anlotinib and Envafolimab in First-line Treatment of Elderly Patients With Small Cell Lung Cancer/ Open-label, Single-arm, Exploratory Phase II Clinical Study
NCT05685550Progression Free Survival(PFS)
Tianjin Medical University Cancer Institute and Hospital
Phase 2
30
Tianjin
2023-04-12
Recruiting
Emergency PWAS in Respiratory Infectious Disease
NCT05336851Viral Infections, Bacterial Infections, Fungal Infections, Mixed Infection
The University of Hong Kong
Observational
2,000
Hong Kong
2023-04-11
Recruiting
Antithrombotic Therapy After Coronary Artery Bypass Grafting Combined With Coronary Endarterectomy
NCT05782270Anticoagulation, Coronary Endarterectomy
China National Center for Cardiovascular Diseases
Phase 4
202
Beijing
2023-04-11
Active, closed
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
NCT05757869Atrial Fibrillation
Janssen Research & Development, LLC
Phase 3
20,284
Beijing, Cangzhou, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Daqing
2023-04-11
Recruiting
The Efficacy and Safety of De-escalated Postoperative Radiotherapy in Locally Advanced HNSCC With pCR/MPR
NCT05854823Head and Neck Squamous Cell Carcinoma
Fifth Affiliated Hospital, Sun Yat-Sen University
Not applicable
23
Zhuhai
2023-04-10
Recruiting
Adjuvant Chemotherapy Combined With Camrelizumab for ⅡA -ⅢA NSCLC Patients
NCT05825443Immunotherapy, Chemotherapy
Nanfang Hospital, Southern Medical University
Phase 2
57
Guandong
2023-04-10
Recruiting
68Ga-FAPI-LM3 PET/CT Imaging in Patients With FAP/SSTR2 Positive Disease and Compared With 18F-FDG
NCT05873777SSTR2, FAP, Positron-Emission Tomography
The First Affiliated Hospital of Xiamen University
Not applicable
30
Xiamen
2023-04-09
Recruiting
Pyrotinib in Women With High-risk in Early Stage Breast Cancer
NCT05834764HER2-positive Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2
188
Nanjing
2023-04-08
Recruiting
Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction
NCT05410925ST Elevation Myocardial Infarction
The First Affiliated Hospital with Nanjing Medical University
Phase 4
2,260
Nanjing, Changzhou, Chongqing, Dalian, Daqing, Dongguan, Fengcheng, Guangzhou
2023-04-08
Recruiting
IVUS-guided DES Implantation in Coronary Calcification
NCT05800002Coronary Artery Disease
Nanjing First Hospital, Nanjing Medical University
Not applicable
864
Nanjing
2023-04-07
Recruiting
Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke
NCT05686642Acute Ischemic Stroke
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 2
300
Beijing, Guangzhou, Luoyang, Hengshui, Daqing, Wuhan, Baotou, Huai'an
2023-04-06
Recruiting
A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer
NCT05754853Advanced or Metastatic Urothelium Cancer
Shanghai Miracogen Inc.
Phase 3
290
Beijing
2023-04-06
Recruiting
Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors
NCT05701709Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1
395
Shanghai
2023-04-06
Active, closed
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma
NCT05126719Recurrent or Metastatic Nasopharyngeal Carcinoma
Lepu Biopharma Co., Ltd.
Phase 2
238
Beijing, Chongqing, Fuzhou, Guangzhou, Maoming, Shantou, Shaoguan, Zhongshan
2023-04-06
By invitation
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
NCT05669989Plasma Cell Myeloma
Sanofi
Phase 2
70
Tianjin
2023-04-05
Active, closed
A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
NCT05704049Relapsed/Refractory Multiple Myeloma
Sanofi
Phase 2
118
Changsha, Guangzhou, Nanchang, Shenyang, Tianjin, Wuhan
2023-04-05
Active, closed
A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple Myeloma
NCT05860036Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
40
Tianjin
2023-04-04
Recruiting
A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN
NCT05751512Squamous Cell Carcinoma of the Head and Neck
Lepu Biopharma Co., Ltd.
Phase 3
180
Shanghai
2023-04-04
Recruiting
Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC
NCT05800340Non-Small Cell Lung Cancer, RET Driver Mutation, BRAF V600 Mutation, Erb-B2 Receptor Tyrosine Kinase Exon 20 Mutation
Guangdong Provincial People's Hospital
Phase 2
30
Guanzhou
2023-04-04
Recruiting
4 Courses vs 2 Courses of Pembrolizumab Combined With Carboplatin and Albumin-binding Paclitaxel of Neoadjuvant Therapy in HNSCC
NCT05980702HNSCC, Oral Cancer, PD-1
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
192
Guangzhou
2023-04-04
Recruiting
A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors
NCT05636215Locally Advanced Unresectable or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1/2
368
Beijing, Chongqing
2023-04-04
Active, closed
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
NCT05618028Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, B Cell Malignancies, Non-Hodgkin's Lymphoma
AbbVie
Phase 1
78
2023-04-04
Recruiting
To Evaluate the Efficacy and Safety of Ipsilateral Supraclavicular Lymph Node Dissection for Breast Cancer Patients
NCT06605521Locally Advanced Breast Cancer
Henan Cancer Hospital
Observational
300
Zhengzhou
2023-04-04
Recruiting
REmimazolam vs Propofol Total Intravenous Anesthesia on Outcomes After Major Noncardiac SurgEry
NCT05728775Anesthesia, Surgery-Complications
Nanfang Hospital, Southern Medical University
Phase 4
7,188
Hefei, Huainan, Suzhou, Beijing, Chongqing, Foshan, Guangzhou, Zhongshan
2023-04-03
Active, closed
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies
NCT05794906Biochemically Recurrent Prostate Cancer
Bayer
Phase 3
985
Beijing, Wuhan, Changsha, Nanjing, Shanghai, Chengdu, Tianjin, Hangzhou
2023-04-03
Active, closed
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
NCT05769777Dermatitis Atopic
Sanofi
Phase 2
999
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jingzhou
2023-04-03
Recruiting
Efficacy and Safety of Penpulimab Combined With Anlotinib and Chemotherapy
NCT06586242Esophageal Cancer
Xijing Hospital
Phase 2
194
Xi'an
2023-04-03
Active, closed
CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors
NCT05631899Solid Tumor, Adult, EphA2 Overexpression, KRAS G12V, KRAS G12C
Chinese PLA General Hospital
Phase 1
9
Beijing
2023-04-03
Not yet open
Effect of Incentive Integrated E-IBD Chronic Disease Management Model on the Quality of Life in IBD Patients
NCT05719766Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
200
Hangzhou, Huzhou, Shanghai, Shaoxing
2023-04-01
Rows per page Showing 15401–15500 of 19052
Previous 153 154 155 156 157 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site. Derived from ClinicalTrials.gov. Retrieved 23 September 2026. https://priyalifescience.com/clinical-trials-china?page=155

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →
→

Browse trials by condition

Breast Cancer (416) Advanced Solid Tumors (183) Gastric Cancer (183) Colorectal Cancer (179) Hepatocellular Carcinoma (161) Advanced Solid Tumor (159) Solid Tumor (145) Non-Small Cell Lung Cancer (144) Acute Ischemic Stroke (138) Lung Cancer (134) Pancreatic Cancer (132) Non-small Cell Lung Cancer (131) Multiple Myeloma (126) Coronary Artery Disease (111) Prostate Cancer (111)
→

Browse trials by site location

Beijing (5484) Shanghai (3827) Guangzhou (3318) Hangzhou (1812) Wuhan (1343) Chengdu (1291) Nanjing (1193) Changsha (1154) Chongqing (1056) Fuzhou (1018) Tianjin (940) Zhengzhou (921) Hefei (875) Jinan (785) Changchun (641)
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.